R-CCS Cafe 第234回 第3部

Since the late 2010s, applications of Artificial Intelligence (AI) to drug discovery have become very important issues in pharmaceutical industry. HPC- and AI-driven Drug Development Platform Division have organized a consortium (LINC) with pharmaceutical and IT companies to build AI technologies including GCN-based prediction models, MCTS-based chemical structure generation models. After the first phase of LINC, AMED and our division started a new national project named DAIIA collaborated with 18 pharmaceutical companies. Using more than 10 million of data, we have been constructing more accurate and applicable AI models for drug discovery.